VIMOS Ultra-Deep Survey (VUDS): IGM transmission towards galaxies with 2.5 < z < 5.5 and the colour selection of high-redshift galaxies

International audienceThe observed UV rest-frame spectra of distant galaxies are the result of their intrinsic emission combined with absorption along the line of sight produced by the inter-galactic medium (IGM). Here we analyse the evolution of the mean IGM transmission Tr(Lyalpha) and its dispersion along the line of sight for 2127 galaxies with 2.5 in the VIMOS Ultra Deep Survey (VUDS). We fitted model spectra combined with a range of IGM transmission to the galaxy spectra using the spectral fitting algorithm GOSSIP+. We used these fits to derive the mean IGM transmission towards each galaxy for several redshift slices from z = 2.5 to z = 5.5. We found that the mean IGM transmission defined as Tr(Lyalpha) = e^- tau (with tau as the HI optical depth) is 79%, 69%, 59%, 55%, and 46% at redshifts 2.75, 3.22, 3.70, 4.23, and 4.77, respectively. We compared these results to measurements obtained from quasar lines of sight and found that the IGM transmission towards galaxies is in excellent agreement with quasar values up to redshift z ~ 4. We found tentative evidence for a higher IGM transmission at z >= 4 compared to results from QSOs, but a degeneracy between dust extinction and IGM prevents us from firmly concluding whether the internal dust extinction for star-forming galaxies at z > 4 takes a mean value significantly in excess of E(B-V) > 0.15. Most importantly, we found a large dispersion of IGM transmission along the lines of sight towards distant galaxies with 68% of the distribution within 10 to 17% of the median value in deltaz = 0.5 bins, similar to what is found on the lines of sight towards QSOs. We demonstrate that taking this broad range of IGM transmission into account is important when selecting high-redshift galaxies based on their colour properties (e.g. LBG or photometric redshiftselection) because failing to do so causes a significant incompleteness in selecting high-redshift galaxy populations. We finally discuss the observed IGM properties and speculate that the broad range of observed transmissions might be the result of cosmic variance and clustering along lines of sight. This clearly shows that the sources that cause this extinction need to be more completely modelled

A journey from the outskirts to the cores of groups. I. Color- and mass-segregation in 20K-zCOSMOS groups

Aims. Using the group catalog obtained from zCOSMOS spectroscopic data and the complementary photometric data from the COSMOS survey, we explore segregation effects occurring in groups of galaxies at intermediate/high redshifts. Our aim is to reveal if, and how significantly, group environment affects the evolution of infalling galaxies. Methods. We built two composite groups at intermediate (0.2 <= z <= 0.45) and high (0.45 < z <= 0.8) redshifts, and we divided the corresponding composite group galaxies into three samples according to their distance from the group center. The samples roughly correspond to galaxies located in a group's inner core, intermediate, and infall region. We explored how galaxy stellar masses and colors - working in narrow bins of stellar masses - vary as a function of the galaxy distance from the group center. Results. We found that the most massive galaxies in our sample (log(M-gal/M-circle dot) >= 10.6) do not display any strong group-centric dependence of the fractions of red/blue objects. For galaxies of lower masses (9.8 <= log(M-gal/M-circle dot) <= 10.6) there is a radial dependence in the changing mix of red and blue galaxies. This dependence is most evident in poor groups, whereas richer groups do not display any obvious trend of the blue fraction. Interestingly, mass segregation shows the opposite behavior: it is visible only in rich groups, while poorer groups have a a constant mix of galaxy stellar masses as a function of radius. Conclusions. These findings can be explained in a simple scenario where color- and mass-segregation originate from different physical processes. While dynamical friction is the obvious cause for establishing mass segregation, both starvation and galaxy-galaxy collisions are plausible mechanisms to quench star formation in groups at a faster rate than in the field. In poorer groups the environmental effects are caught in action superimposed to secular galaxy evolution. Their member galaxies display increasing blue fractions when moving from the group center to more external regions, presumably reflecting the recent accretion history of these groups

The VIMOS VLT Deep Survey final data release: a spectroscopic sample of 35 016 galaxies and AGN out to z ~ 6.7 selected with 17.5 64 iAB 64 24.75

Context. Deep representative surveys of galaxies at different epochs are needed to make progress in understanding galaxy evolution. Aims: We describe the completed VIMOS VLT Deep Survey and the final data release of 35 016 galaxies and type-I AGN with measured spectroscopic redshifts covering all epochs up to redshift z ~ 6.7, in areas from 0.142 to 8.7 square degrees, and volumes from 0.5 7 106 to 2 7 107 h-3 Mpc3. Methods: We selected samples of galaxies based solely on their i-band magnitude reaching iAB = 24.75. Spectra were obtained with VIMOS on the ESO-VLT integrating 0.75 h, 4.5 h, and 18 h for the Wide, Deep, and Ultra-Deep nested surveys, respectively. We demonstrate that any "redshift desert" can be crossed successfully using spectra covering 3650 64 \u3bb 64 9350 \uc5. A total of 1263 galaxies were again observed independently within the VVDS and from the VIPERS and MASSIV surveys. They were used to establish the redshift measurements reliability, to assess completeness in the VVDS sample, and to provide a weighting scheme taking the survey selection function into account. We describe the main properties of the VVDS samples, and the VVDS is compared to other spectroscopic surveys in the literature. Results: In total we have obtained spectroscopic redshifts for 34 594 galaxies, 422 type-I AGN, and 12 430 Galactic stars. The survey enabled identifying galaxies up to very high redshifts with 4669 redshifts in 1 64 zspec 64 2, 561 in 2 64 zspec 64 3, and 468 with zspec > 3, and specific populations like Lyman-\u3b1 emitters were identified out to z = 6.62. We show that the VVDS occupies a unique place in the parameter space defined by area, depth, redshift coverage, and number of spectra. Conclusions: The VIMOS VLT Deep Survey provides a comprehensive survey of the distant universe, covering all epochs since z ~ 6, or more than 12 Gyr of cosmic time, with a uniform selection, which is the largest such sample to date. A wealth of science results derived from the VVDS have shed new light on the evolution of galaxies and AGN and on their distribution in space over this large cosmic time. The VVDS further demonstrates that large deep spectroscopic redshift surveys over all these epochs in the distant Universe are a key tool to observational cosmology. To enhance the legacy value of the survey, a final public release of the complete VVDS spectroscopic redshift sample is available at http://cesam.lam.fr/vvds

The Radial and Azimuthal Profiles of Mg II Absorption around 0.5 < z &lt; 0.9 zCOSMOS Galaxies of Different Colors, Masses, and Environments

We map the radial and azimuthal distribution of Mg II gas within ~ 200 kpc (physical) of ~ 4000 galaxies at redshifts 0.5 1. We investigate the variation of Mg II rest-frame equivalent width (EW) as a function of the radial impact parameter for different subsets of foreground galaxies selected in terms of their rest-frame colors and masses. Blue galaxies have a significantly higher average Mg II EW at close galactocentric radii as compared to the red galaxies. Among the blue galaxies, there is a correlation between Mg II EW and galactic stellar mass of the host galaxy. We also find that the distribution of Mg II absorption around group galaxies is more extended than that for non-group galaxies, and that groups as a whole have more extended radial profiles than individual galaxies. Interestingly, these effects can be satisfactorily modeled by a simple superposition of the absorption profiles of individual member galaxies, assuming that these are the same as those of non-group galaxies, suggesting that the group environment may not significantly enhance or diminish the Mg II absorption of individual galaxies. We show that there is a strong azimuthal dependence of the Mg II absorption within 50 kpc of inclined disk-dominated galaxies, indicating the presence of a strongly bipolar outflow aligned along the disk rotation axis. There is no significant dependence of Mg II absorption on the apparent inclination angle of disk-dominated galaxies

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: Results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

BACKGROUND: A fixed-ratio combination of the basal insulin analogue insulin degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide has been developed as a once-daily injection for the treatment of type 2 diabetes. We aimed to compare combined insulin degludec-liraglutide (IDegLira) with its components given alone in insulin-naive patients. METHODS: In this phase 3, 26-week, open-label, randomised trial, adults with type 2 diabetes, HbA1c of 7-10% (inclusive), a BMI of 40 kg/m(2) or less, and treated with metformin with or without pioglitazone were randomly assigned (2:1:1) to daily injections of IDegLira, insulin degludec, or liraglutide (1\ub78 mg per day). IDegLira and insulin degludec were titrated to achieve a self-measured prebreakfast plasma glucose concentration of 4-5 mmol/L. The primary endpoint was change in HbA1c after 26 weeks of treatment, and the main objective was to assess the non-inferiority of IDegLira to insulin degludec (with an upper 95% CI margin of 0\ub73%), and the superiority of IDegLira to liraglutide (with a lower 95% CI margin of 0%). This study is registered with ClinicalTrials.gov, number NCT01336023. FINDINGS: 1663 adults (mean age 55 years [SD 10], HbA1c 8\ub73% [0\ub79], and BMI 31\ub72 kg/m(2) [4\ub78]) were randomly assigned, 834 to IDegLira, 414 to insulin degludec, and 415 to liraglutide. After 26 weeks, mean HbA1c had decreased by 1\ub79% (SD 1\ub71) to 6\ub74% (1\ub70) with IDegLira, by 1\ub74% (1\ub70) to 6\ub79% (1\ub71) with insulin degludec, and by 1\ub73% (1\ub71) to 7\ub70% (1\ub72) with liraglutide. IDegLira was non-inferior to insulin degludec (estimated treatment difference -0\ub747%, 95% CI -0\ub758 to -0\ub736, p<0\ub70001) and superior to liraglutide (-0\ub764%, -0\ub775 to -0\ub753, p<0\ub70001). IDegLira was generally well tolerated; fewer participants in the IDegLira group than in the liraglutide group reported gastrointestinal adverse events (nausea 8\ub78 vs 19\ub77%), although the insulin degludec group had the fewest participants with gastrointestinal adverse events (nausea 3\ub76%). We noted no clinically relevant differences between treatments with respect to standard safety assessments, and the safety profile of IDegLira reflected those of its component parts. The number of confirmed hypoglycaemic events per patient year was 1\ub78 for IDegLira, 0\ub72 for liraglutide, and 2\ub76 for insulin degludec. Serious adverse events occurred in 19 (2%) of 825 patients in the IDegLira group, eight (2%) of 412 in the insulin degludec group, and 14 (3%) of 412 in the liraglutide group. INTERPRETATION: IDegLira combines the clinical advantages of basal insulin and GLP-1 receptor agonist treatment, resulting in improved glycaemic control compared with its components given alone

Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral of surgery

This is the peer reviewed version of the following article: , which has been published in final form at https://doi.org/10.1111/codi.14361. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions."Colorectal Disease © 2018 The Association of Coloproctology of Great Britain and Ireland Introduction: The mainstay of management for locally advanced rectal cancer is chemoradiotherapy followed by surgical resection. Following chemoradiotherapy, a complete response may be detected clinically and radiologically (cCR) prior to surgery or pathologically after surgery (pCR). We aim to report the overall complete pathological response (pCR) rate and the reliability of detecting a cCR by conventional pre-operative imaging. Methods: A pre-planned analysis of the European Society of Coloproctology (ESCP) 2017 audit was performed. Patients treated by elective rectal resection were included. A pCR was defined as a ypT0 N0 EMVI negative primary tumour; a partial response represented any regression from baseline staging following chemoradiotherapy. The primary endpoint was the pCR rate. The secondary endpoint was agreement between post-treatment MRI restaging (yMRI) and final pathological staging. Results: Of 2572 patients undergoing rectal cancer surgery in 277 participating centres across 44 countries, 673 (26.2%) underwent chemoradiotherapy and surgery. The pCR rate was 10.3% (67/649), with a partial response in 35.9% (233/649) patients. Comparison of AJCC stage determined by post-treatment yMRI with final pathology showed understaging in 13% (55/429) and overstaging in 34% (148/429). Agreement between yMRI and final pathology for T-stage, N-stage, or AJCC status were each graded as ‘fair’ only (n = 429, Kappa 0.25, 0.26 and 0.35 respectively). Conclusion: The reported pCR rate of 10% highlights the potential for non-operative management in selected cases. The limited strength of agreement between basic conventional post-chemoradiotherapy imaging assessment techniques and pathology suggest alternative markers of response should be considered, in the context of controlled clinical trials

Risk factors for unfavourable postoperative outcome in patients with Crohn's disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO

Aim: Patient- and disease-related factors, as well as operation technique, all have the potential to impact on postoperative outcome in Crohn's disease. The available evidence is based on small series and often displays conflicting results. The aim was to investigate the effect of preoperative and intra-operative risk factors on 30-day postoperative outcome in patients undergoing surgery for Crohn's disease. Method: This was an international prospective snapshot audit including consecutive patients undergoing right hemicolectomy or ileocaecal resection. The study analysed a subset of patients who underwent surgery for Crohn's disease. The primary outcome measure was the overall Clavien\u2013Dindo postoperative complication rate. The key secondary outcomes were anastomotic leak, reoperation, surgical site infection and length of stay in hospital. Multivariable binary logistic regression analyses were used to produce odds ratios and 95% confidence intervals. Results: In all, 375 resections in 375 patients were included. The median age was 37 and 57.1% were women. In multivariate analyses, postoperative complications were associated with preoperative parenteral nutrition (OR 2.36, 95% CI 1.10\u20134.97), urgent/expedited surgical intervention (OR 2.00, 95% CI 1.13\u20133.55) and unplanned intra-operative adverse events (OR 2.30, 95% CI 1.20\u20134.45). The postoperative length of stay in hospital was prolonged in patients who received preoperative parenteral nutrition (OR 31, 95% CI 1.08\u20131.61) and those who had urgent/expedited operations (OR 1.21, 95% CI 1.07\u20131.37). Conclusion: Preoperative parenteral nutritional support, urgent/expedited operation and unplanned intra-operative adverse events were associated with unfavourable postoperative outcome. Enhanced preoperative optimization and improved planning of operation pathways and timings may improve outcomes for patients

Body mass index and complications following major gastrointestinal surgery: a prospective, international cohort study and meta-analysis.

AIM: Previous studies reported conflicting evidence on the effects of obesity on outcomes after gastrointestinal surgery. The aims of this study were to explore the relationship of obesity with major postoperative complications in an international cohort and to present a meta-analysis of all available prospective data. METHODS: This prospective, multicentre study included adults undergoing both elective and emergency gastrointestinal resection, reversal of stoma or formation of stoma. The primary end-point was 30-day major complications (Clavien-Dindo Grades III-V). A systematic search was undertaken for studies assessing the relationship between obesity and major complications after gastrointestinal surgery. Individual patient meta-analysis was used to analyse pooled results. RESULTS: This study included 2519 patients across 127 centres, of whom 560 (22.2%) were obese. Unadjusted major complication rates were lower in obese vs normal weight patients (13.0% vs 16.2%, respectively), but this did not reach statistical significance (P = 0.863) on multivariate analysis for patients having surgery for either malignant or benign conditions. Individual patient meta-analysis demonstrated that obese patients undergoing surgery for malignancy were at increased risk of major complications (OR 2.10, 95% CI 1.49-2.96, P < 0.001), whereas obese patients undergoing surgery for benign indications were at decreased risk (OR 0.59, 95% CI 0.46-0.75, P < 0.001) compared to normal weight patients. CONCLUSIONS: In our international data, obesity was not found to be associated with major complications following gastrointestinal surgery. Meta-analysis of available prospective data made a novel finding of obesity being associated with different outcomes depending on whether patients were undergoing surgery for benign or malignant disease

Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study

To provide a global, up-to-date picture of the prevalence, treatment, and outcomes of Candida bloodstream infections in intensive care unit patients and compare Candida with bacterial bloodstream infection. DESIGN: A retrospective analysis of the Extended Prevalence of Infection in the ICU Study (EPIC II). Demographic, physiological, infection-related and therapeutic data were collected. Patients were grouped as having Candida, Gram-positive, Gram-negative, and combined Candida/bacterial bloodstream infection. Outcome data were assessed at intensive care unit and hospital discharge. SETTING: EPIC II included 1265 intensive care units in 76 countries. PATIENTS: Patients in participating intensive care units on study day. INTERVENTIONS: None. MEASUREMENT AND MAIN RESULTS: Of the 14,414 patients in EPIC II, 99 patients had Candida bloodstream infections for a prevalence of 6.9 per 1000 patients. Sixty-one patients had candidemia alone and 38 patients had combined bloodstream infections. Candida albicans (n = 70) was the predominant species. Primary therapy included monotherapy with fluconazole (n = 39), caspofungin (n = 16), and a polyene-based product (n = 12). Combination therapy was infrequently used (n = 10). Compared with patients with Gram-positive (n = 420) and Gram-negative (n = 264) bloodstream infections, patients with candidemia were more likely to have solid tumors (p < .05) and appeared to have been in an intensive care unit longer (14 days [range, 5-25 days], 8 days [range, 3-20 days], and 10 days [range, 2-23 days], respectively), but this difference was not statistically significant. Severity of illness and organ dysfunction scores were similar between groups. Patients with Candida bloodstream infections, compared with patients with Gram-positive and Gram-negative bloodstream infections, had the greatest crude intensive care unit mortality rates (42.6%, 25.3%, and 29.1%, respectively) and longer intensive care unit lengths of stay (median [interquartile range]) (33 days [18-44], 20 days [9-43], and 21 days [8-46], respectively); however, these differences were not statistically significant. CONCLUSION: Candidemia remains a significant problem in intensive care units patients. In the EPIC II population, Candida albicans was the most common organism and fluconazole remained the predominant antifungal agent used. Candida bloodstream infections are associated with high intensive care unit and hospital mortality rates and resource use